The phantom perception of tinnitus and reduced sound-level tolerance associated with hyperacusis have a high comorbidity and can be debilitating conditions for which there are no widely accepted treatments. One factor limiting the development of treatments for tinnitus and hyperacusis is the lack of reliable animal behavioral models of these disorders. Therefore, the purpose of this review is to highlight the current animal models of tinnitus and hyperacusis, and to detail the advantages and disadvantages of each paradigm. To date, this is the first review to include models of both tinnitus and hyperacusis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166233 | PMC |
| http://dx.doi.org/10.3389/fneur.2014.00179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stress classification with in-ear heartbeat sounds.
Comput Biol Med
December 2024
École de technologie supérieure, 1100 Notre-Dame St W, Montreal, H3C 1K3, Quebec, Canada; Centre for Interdisciplinary Research in Music Media and Technology (CIRMMT), 527 Rue Sherbrooke O #8, Montréal, QC H3A 1E3, Canada. Electronic address:
Background: Although stress plays a key role in tinnitus and decreased sound tolerance, conventional hearing devices used to manage these conditions are not currently capable of monitoring the wearer's stress level. The aim of this study was to assess the feasibility of stress monitoring with an in-ear device.
Method: In-ear heartbeat sounds and clinical-grade electrocardiography (ECG) signals were simultaneously recorded while 30 healthy young adults underwent a stress protocol.
[Ototoxicity caused by anti-epileptic drugs].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis.
View Article and Find Full Text PDFWhat Do Mismatch Negativity (MMN) Responses Tell Us About Tinnitus?
J Assoc Res Otolaryngol
December 2024
Newcastle University Medical School, Newcastle Upon Tyne, NE2 4HH, UK.
Due to the heterogeneous causes, symptoms and associated comorbidities with tinnitus, there remains an unmet need for a clear biomarker of tinnitus presence. Previous research has suggested a "final pathway" of tinnitus presence, which occurs regardless of the specific mechanisms that resulted in alterations of auditory predictions and, eventually, tinnitus perception. Predictive inference mechanisms have been proposed as the possible basis for this final unifying pathway.
View Article and Find Full Text PDFRisk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis.
Eye (Lond)
December 2024
Center for Ophthalmic Bioinformatics, Cleveland Clinic, Cole Eye Institute, Cleveland, OH, USA.
Background/objectives: Patients with thyroid eye disease (TED) taking teprotumumab have reported audiologic symptoms as a side effect; however, limited real world data and large sample sizes have been utilized to evaluate this relationship.
Methods: A retrospective cohort study was created in TriNetX to identify patients with TED utilizing ICD-10, CPT, and Healthcare Common Procedure coding systems. TED patients with and without teprotumumab treatment were analysed with greedy one-to-one propensity matching.
GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Otol Neurotol
January 2025
Cedars-Sinai Medical Center, Division of Otolaryngology-Head and Neck Surgery, Los Angeles, CA.
Introduction: GLP-1 receptor agonists (GLP-1 RAs) have gained traction in the management of obesity. There is limited literature on the implications of GLP-1 RAs in the field of otolaryngology.
Methods: We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!